NCAM1 and ameloblastoma: We examined neuroendocrine markers, including CD56, SYP, and CgA, in 36 ameloblastomas and identified five specimens that exhibited the immunoexpression of CD56 and SYP, suggesting neuroendocrine differentiation in ameloblastomas.